News & Updates
Filter by Specialty:
Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial
In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).
Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial
30 Jun 2025
Diabetes in CHD patients ups risk of hepatocellular carcinoma
The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.
Diabetes in CHD patients ups risk of hepatocellular carcinoma
26 Jun 2025
BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines
A retrospective cohort study of >11,000 Hong Kong patients who initiated anthracycline-based chemotherapy found that both body-mass index (BMI) and glycaemic status significantly affect cardiovascular (CV) risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes.
BMI and glycaemic status significantly affect CV risk in patients treated with anthracyclines
24 Jun 2025
Analogue bests human insulin in T2D patients with kidney failure
Analogue insulin demonstrates superiority over human insulin in terms of survival among patients with kidney failure and type 2 diabetes (T2D) who are receiving peritoneal dialysis, according to a study presented at ERA 2025.